Myelodysplastic syndrome 2 translocation-associated long non-coding RNA (MDS2)

**Myelodysplastic syndrome 2 translocation-associated (MDS2)** is not a protein-coding gene, but rather a long non-coding RNA (lncRNA) gene located on chromosome 8 in humans[1][5]. The gene is annotated in several genome resources and associated with diseases such as myelodysplastic syndrome and glioma susceptibility, but its biological function remains largely uncharacterized and there is no evidence that it acts as a therapeutic target, receptor, enzyme, transporter, or other conventional druggable protein target class. Naming conventions describing it as a \"protein\" are incorrect, as MDS2 is a lncRNA[1][5]. MDS2 should not be described as a protein or receptor, nor does it have any established interacting drugs or known mechanism of action in pharmacology literature[5]. The protein-centric description in your query is inaccurate; there is no evidence from the scientific literature or gene databases that an \"MDS2 protein\" exists. The main relevance of MDS2 is in genomic studies describing translocation breakpoints in myelodysplastic syndromes (MDS), but not as a functional or therapeutic target gene or protein[1][5].

Other names

Myelodysplastic syndrome 2 translocation-associated protein, MDS2MDS2 lncRNA